Please ensure Javascript is enabled for purposes of website accessibility

Is AnaptysBio Stock a Buy?

By David Haen – Apr 10, 2020 at 6:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This antibody drug developer can be had for fire-sale prices.

AnaptysBio (ANAB 4.81%) checks many boxes that make it an attractive biotech investment: It's got a sizable cash position, reputable pharma partners, and a promising drug pipeline. Throw in a depressed stock price and the company looks even more appealing. Is now the time for investors to jump in?

World map with laptop of stock going up then down and man scratching his head

Image source: Getty Images.

AnaptysBio had $428.5 million in cash and equivalents on its books at the end of 2019, providing ample resources for its research and development activities. The company expects a net cash burn of $60 million in 2020 and claims its current funds can carry operations into 2023. Cash-rich companies are better positioned to weather R&D setbacks or macro challenges like COVID-19, compared with companies in need of near-term funding. 

In 2014, AnaptysBio forged a broad oncology partnership with Tesaro, an oncology company acquired by GlaxoSmithKline (GSK -0.56%)in 2019. It also created an inflammation-focused alliance with Celgene, now part of Bristol Myers Squibb (BMY 0.30%), in 2011.

The partnerships will help advance more compounds in parallel than AnaptysBio could do alone, but they are not huge moneymakers -- not because they were bad deals, but because they were reached in the very early stages of drug development. For example, Bristol Myers Squibb will pay AnaptysBio up to $18 million for achieving certain R&D milestones, $35 million in regulatory milestones (submissions and approvals), and a single-digit percentage of sales as royalties.

In the fourth quarter, GlaxoSmithKline filed for U.S. Food and Drug Administration (FDA) approval of Tesaro's dostarlimab as a treatment for endometrial cancer. AnaptysBio stands to earn $10 million from GlaxoSmithKline when the FDA accepts the application and another $20 million if the FDA approves the drug.

Dostarlimab, a latecomer to the field of antibodies targeting a protein called PD-1 (Bristol Myers Squibb's Opdivo and Merck's (MRK -0.40%) Keytruda are others), has been effective for patients with advanced stages of endometrial cancer for whom prior therapies have failed.

The early-stage R&D pact that AnaptysBio cemented with Celgene back in 2011 delivered a number of novel antibodies in 2014. For its part, Bristol Myers Squibb is currently advancing two anti-inflammatory molecules. One targets PD-1 and is in phase 1 trials, and the second, for an undisclosed target, is in preclinical development.

The stock's wild ride

AnaptysBio made and lost fortunes for early public investors. The company's IPO priced at $15 per share on Jan. 31, 2017. In October of the same year, management took advantage of a swelling stock price to raise an additional $212.3 million at $68.50 per share. The stock continued to climb, peaking on March 2, 2018, at $128.55. As it began to recede from its highs, AnaptysBio pulled off another financing in September 2018. The company raised $227.5 million at a price of $94.46 per share. That's more than a sixfold return from the original IPO.

Unfortunately, the stock has not revisited those levels again. The price stumbled downward for the rest of 2018 and most of 2019. Then, last November, the stock imploded. More than two-thirds of the stock's price disappeared; it went from $36.16 to $10.18 in a single day following the failure of its lead drug in a phase 2 trial for atopic dermatitis, better known as eczema.

The stock currently trades in the $15 range, roughly 90% off from its former highs. Does this valuation make it attractive?

Betting against AnaptysBio

Some investors remain skeptical regarding AnaptysBio's future. As of mid-March, 35% of the shares available to trade are short. This means investors are more bearish on the stock than on the average S&P company; the percentage of shares sold short across the entire index is 22%. That said, it's possible some of the short selling is not aimed specifically at the company, but is a result of investors trying to broadly short companies because of the current COVID-19-induced market downturn.

On a positive note, if the company surprises biotech investors with good news -- say, another partnership or positive clinical trial results -- then the stock could jump, with short sellers forced to buy the stock to "cover" their position. In this way, large short positions can amplify a stock's natural response to good news.

What's next?

AnaptysBio plans to report in the first half of this year on its phase 2 clinical trial of etokimab as a treatment for chronic rhinosinusitis (sinus infection) with nasal polyps. This is the same drug that failed in November for eczema. Naturally, investors remain in a "show me" mode, waiting to see whether the drug still has legs or should be written off altogether. Likewise, I fall into the camp of waiting until after the etokimab results to reconsider an investment.


David Haen has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Bristol Myers Squibb. The Motley Fool recommends AnaptysBio. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AnaptysBio Stock Quote
$25.70 (4.81%) $1.18
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$85.84 (-0.40%) $0.34
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$70.36 (0.30%) $0.21
GSK Stock Quote
$28.66 (-0.56%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.